CellAegis Announces Completion of Patient Enrollment in Danish Investigator Sponsored Clinical Trial Using autoRIC® Device TORONTO, May 17, 2018 (GLOBE NEWSWIRE) -- CellAegis Devices Inc. (“CellAegis” or the “Company”), a commercial-stage medical device company advancing innovative, non-invasive, safe and cost-effective...

CellAegis Announces First Distribution Agreement for autoRIC® in Europe TORONTO, April 24, 2018 (GLOBE NEWSWIRE) -- CellAegis Devices Inc. (“CellAegis”) a commercial-stage medical device company advancing innovative, non-invasive, safe and cost-effective solutions for...

CellAegis Strengthens Management Team to Support Future Growth TORONTO, April 17, 2018 (GLOBE NEWSWIRE) -- CellAegis Devices Inc. (“CellAegis” or the “Company”), a commercial-stage medical device company advancing innovative, non-invasive, safe and...

CellAegis Announces First Patients Enrolled in U.S. SHIELD Pivotal Clinical Trial TORONTO, April 10, 2018 (GLOBE NEWSWIRE) -- CellAegis Devices Inc. (“CellAegis” or the “Company”), a commercial-stage medical device company advancing innovative, non-invasive, safe and...